CA2753436C - Estrogen receptor ligands and methods of use thereof - Google Patents

Estrogen receptor ligands and methods of use thereof Download PDF

Info

Publication number
CA2753436C
CA2753436C CA2753436A CA2753436A CA2753436C CA 2753436 C CA2753436 C CA 2753436C CA 2753436 A CA2753436 A CA 2753436A CA 2753436 A CA2753436 A CA 2753436A CA 2753436 C CA2753436 C CA 2753436C
Authority
CA
Canada
Prior art keywords
compound
levels
serum testosterone
testosterone levels
another embodiment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2753436A
Other languages
English (en)
French (fr)
Other versions
CA2753436A1 (en
Inventor
James T. Dalton
Mitchell S. Steiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncternal Therapeutics Inc
Original Assignee
GTx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GTx Inc filed Critical GTx Inc
Publication of CA2753436A1 publication Critical patent/CA2753436A1/en
Application granted granted Critical
Publication of CA2753436C publication Critical patent/CA2753436C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pain & Pain Management (AREA)
CA2753436A 2009-02-23 2010-02-23 Estrogen receptor ligands and methods of use thereof Expired - Fee Related CA2753436C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US15470709P 2009-02-23 2009-02-23
US61/154,707 2009-02-23
US16898309P 2009-04-14 2009-04-14
US61/168,983 2009-04-14
US26166909P 2009-11-16 2009-11-16
US61/261,669 2009-11-16
PCT/US2010/025032 WO2010096801A1 (en) 2009-02-23 2010-02-23 Estrogen receptor ligands and methods of use thereof

Publications (2)

Publication Number Publication Date
CA2753436A1 CA2753436A1 (en) 2010-08-26
CA2753436C true CA2753436C (en) 2016-05-24

Family

ID=42634248

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2753436A Expired - Fee Related CA2753436C (en) 2009-02-23 2010-02-23 Estrogen receptor ligands and methods of use thereof

Country Status (10)

Country Link
EP (1) EP2398322A4 (ru)
JP (1) JP5611991B2 (ru)
KR (3) KR101458539B1 (ru)
CN (1) CN102413692B (ru)
BR (1) BR112014004008A2 (ru)
CA (1) CA2753436C (ru)
IL (1) IL214805A0 (ru)
MX (1) MX340753B (ru)
RU (1) RU2543339C2 (ru)
WO (1) WO2010096801A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9409856B2 (en) 2005-11-28 2016-08-09 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US9624161B2 (en) 2009-02-23 2017-04-18 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
WO2010141630A1 (en) * 2009-06-03 2010-12-09 University Of Southern California Compositions and methods for treatment of cancer by disrupting the lh/lhr signaling pathway
KR20140064906A (ko) * 2011-08-23 2014-05-28 지티엑스, 인코포레이티드 에스트로겐 수용체 리간드 및 그의 이용 방법
WO2013142390A1 (en) * 2012-03-21 2013-09-26 Gtx, Inc. Aldo-keto reductase subfamily 1c3 (akr1c3) inhibitors
WO2014039820A1 (en) * 2012-09-07 2014-03-13 Gtx, Inc. Aldo-keto reductase subfamily 1c3 (akr1c3) inhibitors
WO2023220117A1 (en) * 2022-05-10 2023-11-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods of treating dilated cardiomyopathy and heart failure

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020192310A1 (en) * 2001-02-02 2002-12-19 Bland Jeffrey S. Medical composition for managing hormone balance
US20060287282A1 (en) * 2001-06-25 2006-12-21 Steiner Mitchell S Compositions comprising a SARM ad GnRH agonist or a GnRH antagonist, and methods of use thereof
US7601739B2 (en) * 2003-08-08 2009-10-13 Virgina Commonwealth University Compounds having antiestrogenic and tissue selective estrogenic properties, and compounds with anti-androgenic properties for treatment of prostate cancer and androgen receptor dependent diseases
US8158828B2 (en) * 2005-11-28 2012-04-17 Gtx, Inc. Nuclear receptor binding agents
MX2008006885A (es) * 2005-11-28 2008-10-20 Gtx Inc Agentes de enlace de receptores nucleares.
US8546451B2 (en) * 2005-11-28 2013-10-01 Gtx, Inc. Estrogen receptor ligands and methods of use thereof

Also Published As

Publication number Publication date
EP2398322A4 (en) 2012-12-05
CA2753436A1 (en) 2010-08-26
EP2398322A1 (en) 2011-12-28
MX340753B (es) 2016-07-25
KR20110131227A (ko) 2011-12-06
CN102413692B (zh) 2015-01-07
IL214805A0 (en) 2011-11-30
RU2011137324A (ru) 2013-03-27
CN102413692A (zh) 2012-04-11
RU2543339C2 (ru) 2015-02-27
AU2010215809A1 (en) 2011-09-22
KR20150135547A (ko) 2015-12-02
KR20130101146A (ko) 2013-09-12
KR101458539B1 (ko) 2014-11-10
BR112014004008A2 (pt) 2017-03-28
WO2010096801A1 (en) 2010-08-26
JP5611991B2 (ja) 2014-10-22
MX2011008879A (es) 2012-04-30
JP2012518654A (ja) 2012-08-16

Similar Documents

Publication Publication Date Title
CA2753436C (en) Estrogen receptor ligands and methods of use thereof
US9051267B2 (en) Estrogen receptor ligands and methods of use thereof
US9427418B2 (en) Estrogen receptor ligands and methods of use thereof
EP3285757B1 (en) Selective androgen receptor degrader (sard) ligands and methods of use thereof
US20140187641A1 (en) Estrogen receptor ligands and methods of use thereof
US11591290B2 (en) Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US9409856B2 (en) Estrogen receptor ligands and methods of use thereof
US9624161B2 (en) Estrogen receptor ligands and methods of use thereof
US20140057985A1 (en) Estrogen receptor ligands and methods of use thereof
AU2012312902B2 (en) Estrogen receptor ligands and methods of use thereof
AU2010215809B2 (en) Estrogen receptor ligands and methods of use thereof
US20140057946A1 (en) Estrogen receptor ligands and methods of use thereof
WO2013043304A9 (en) Estrogen receptor ligands and methods of use thereof
WO2020073017A1 (en) Selective androgen receptor degrader (sard) ligands and methods of use thereof

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20180223